High-dose megestrol acetate as third-line endocrine therapy for metastatic breast cancer.
High-dose megestrol acetate (800 mg/day) was administered to 34 patients as third-line endocrine therapy for metastatic breast cancer after progression on standard-dose megestrol acetate (160 mg/day). Among the 32 evaluable patients, no complete or partial response occurred. Ten patients remained stable and 22 progressed. No patients remained on study. Median time to progression was 2 months (range, 1-13 months). The use of high-dose megestrol acetate did not result in objective responses but may have been effective in delaying progression in one third of patients.
Cruz
J M
JM
Comprehensive Cancer Center of Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27157-1082.
Muss
H B
HB
Russell
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001835:Body Weight / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008535:Megestrol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D008875:Middle Aged; D009362:Neoplasm Metastasis
D008535:Megestrol; D019290:Megestrol Acetate